IPSEN (OTCMKTS:IPSEY) Shares Gap Down – Here’s What Happened

IPSEN (OTCMKTS:IPSEY)’s stock price gapped down before the market opened on Monday . The stock had previously closed at $47.68, but opened at $44.9475. IPSEN shares last traded at $44.9475, with a volume of 1,023 shares trading hands.

Wall Street Analyst Weigh In

IPSEY has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a research note on Thursday, May 14th. Jefferies Financial Group lowered IPSEN to an “underperform” rating in a research report on Sunday. HC Wainwright reiterated a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Finally, Zacks Research upgraded IPSEN to a “hold” rating in a research report on Friday, May 29th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold”.

IPSEN Price Performance

The company’s 50-day moving average price is $45.87 and its 200 day moving average price is $45.56.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).